161 related articles for article (PubMed ID: 37073788)
1. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy.
Marcinak CT; Parker WF; Parikh AA; Datta J; Maithel SK; Kooby DA; Burkard ME; Kim HJ; LeCompte MT; Afshar M; Churpek MM; Zafar SN
J Surg Oncol; 2023 Aug; 128(2):280-288. PubMed ID: 37073788
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy.
Qiao G; Ilagan CH; Fernandez-Del Castillo C; Ferrone CR; Janseen QP; Balachandran VP; Sell NM; Drebin JA; Hank T; Kingham TP; D'Angelica MI; Jarnagin WR; Lillemoe KD; Wei AC; Qadan M
Surgery; 2022 Oct; 172(4):1228-1235. PubMed ID: 35931556
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
[TBL] [Abstract][Full Text] [Related]
5. A Nomogram for Individual Prediction of Poor Prognosis After Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma.
Zhai S; Huo Z; Ying X; Jin J; Wang Y; Lu X; Deng X
Med Sci Monit; 2020 Feb; 26():e918882. PubMed ID: 32088726
[TBL] [Abstract][Full Text] [Related]
6. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
7. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy.
Song KB; Kwon J; Kim YW; Hwang DW; Lee JH; Hong S; Lee JW; Hwang K; Yoo D; Kim SC
J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):227-234. PubMed ID: 30980486
[TBL] [Abstract][Full Text] [Related]
9. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
10. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
12. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
13. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.
Ferrone CR; Kattan MW; Tomlinson JS; Thayer SP; Brennan MF; Warshaw AL
J Clin Oncol; 2005 Oct; 23(30):7529-35. PubMed ID: 16234519
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?
Nakauchi M; Court CM; Tang LH; Gönen M; Janjigian YY; Maron SB; Molena D; Coit DG; Brennan MF; Strong VE
J Am Coll Surg; 2022 Aug; 235(2):294-304. PubMed ID: 35839406
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection.
Xie T; Wang X; Li M; Tong T; Yu X; Zhou Z
Eur Radiol; 2020 May; 30(5):2513-2524. PubMed ID: 32006171
[TBL] [Abstract][Full Text] [Related]
16. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
17. A Prognostic Nomogram for Disease-Specific Survival in Patients with Pancreatic Ductal Adenocarcinoma of the Head of the Pancreas Following Pancreaticoduodenectomy.
Li HB; Zhou J; Zhao FQ
Med Sci Monit; 2018 Sep; 24():6313-6321. PubMed ID: 30198517
[TBL] [Abstract][Full Text] [Related]
18. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
20. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
